arrow
Return

How can artificial intelligence optimize value-based contracting?

delete2022-11-18
delete2
delete
OA
AI
J
José Luís Poveda *
R
Rosa Bretón‐Romero
C
Carlos Del Rio‐Bermudez
M
Miren Taberna
I
Ignacio Hernández Medrano
DOI:10.1186/s40545-022-00475-3delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Efforts in the pharmaceutical market have been aimed at ensuring that the benefits obtained from the introduction of new therapies justify the associated costs. In recent years, drug payment models in healthcare have undergone a dramatic shift from focusing on volume (i.e., size of the target clinical population) to focusing on value (i.e., drug performance in real-world settings). In this context, value-based contracts (VBCs) were designed to align the payment of a drug to its clinical performance outside clinical trials by evaluating the effectiveness using real-word evidence (RWE). Despite their widespread implementation, different factors jeopardize the application of VBCs to most marketed drugs in a near future, including the need for easily measurable and relevant outcomes associated with clinical improvements, and access to a large patient population to assess said outcomes. Here, we argue that the extraction and analysis of massive amounts of RWE captured in patients' electronic health records (EHRs) will circumvent these issues and optimize negotiations in VBCs. Particularly, the use of Natural Language Processing (NLP) has proven successful in the analysis of structured and unstructured clinical information in EHRs in multicenter research studies. Thus, the application of NLP to analyze patient-centered information in EHRs in the context of innovative contracting can be utterly beneficial as it enables the real-time evaluation of treatment response and financial impact in real-world settings.
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Journal of Pharmaceutical Policy and Practice cover
Journal of Pharmaceutical Policy and Practice
IF:
2.5
Papers:
880
Citations:
1.6K

Organization

No organization information available
Cited Papers

Cited Papers

errShare
errSave
MicroCT Analysis of Micro-Nano Titanium Implant Surface on the Osseointegration
err2015-01-01
err0
PREAI
errJaesam Ban; Seongsoo Kang; Jihyun Kim; Kwangmin Lee; Hyunpil Lim; Mongsook Vang; Hongso Yang; Gyejeong Oh; Hyunseung Kim; Gabwoon Hwang; Yongho Jung; Kyungku Lee; Sangwon Park; Kwidug Yun
errShare
errSave
International trade.
err2007-03-28
err0
PREAI
errF. Dusuncelı; J. A. Wood; A. Gupta; M. Yadav; S. S. Yadav
errShare
errSave
Box dimension of trajectories of some discrete dynamical systems
err2007-10-01
err0
errOAAI
errNeven Elezović; Vesna Županović; Darko Žubrinić
errShare
errSave
Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary View
err2016-12-16
err674
errOAAI
errLuo, Wei; Phung, Dinh; Tran, Truyen; Gupta, Sunil; Rana, Santu; Karmakar, Chandan; Shilton, Alistair; Yearwood, John; Dimitrova, Nevenka; Ho, Tu Bao; Venkatesh, Svetha; Berk, Michael
errShare
errSave
errShare
errSave
Evaluation of Creatine Phosphokinase Activity as a Means of Determining Cooking End-Point Temperature
err1994-02-01
err0
errOAAI
errWilliam E. Townsend; Gayle K. Searcy; Carl E. Davis; Ruel L. Wilson
errShare
errSave
err
IF0
err
err0
PREAI
err
errShare
errSave
The Genus Amblyomma Koch, 1844
err2018-02-15
err0
PREAI
errIvan G. Horak; Heloise Heyne; Roy Williams; G. James Gallivan; Arthur M. Spickett; J. Dürr Bezuidenhout; Agustín Estrada-Peña
errShare
errSave
researcher View more